Dynavax Technologies Announces First Quarter 2005 Earnings Conference Call
BERKELEY, Calif., April 20 /PRNewswire/ -- Dynavax Technologies (Nasdaq: DVAX), working in vaccines for ragweed allergy and hepatitis B, will hold its quarterly conference call to discuss 2005 first quarter results on Thursday, April 28, 2005, at 5:00 p.m. Eastern Time.
This call is being webcast by Thomson/CCBN and can be accessed at the Dynavax Technologies website at www.dynavax.com on the Webcast page under Investors.
The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.fulldisclosure.com, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three initial indications: ragweed allergy immunotherapeutic, currently in a Phase 2/3 clinical trial; a Hepatitis B vaccine, currently in a Phase 2/3 clinical trial; and an asthma immunotherapeutic that has completed a Phase 2 exploratory trial.
SOURCE Dynavax Technologies
04/20/2005
CONTACT: Jane Green, VP Corporate Communications of Dynavax
Technologies, +1-510-665-4630, JGreen@DVAX.com
Web site: http://www.streetevents.com
Web site: http://www.fulldisclosure.com
Web site: http://www.dynavax.com
(DVAX)
04/20/2005 17:14 EDT http://www.prnewswire.com